MediMavericks · Commercial strategy for MedTech, pharma & healthcare SaaS

When healthcare
revenue stalls,
we find out why.

MediMavericks works with medical device, pharma and healthcare SaaS companies whose growth has stalled, whose launch is coming, or whose sales still depend on the founder. We diagnose what is holding revenue back, then build and lead the fix: go-to-market strategy, sales playbooks and fractional commercial leadership.

Book a free health check Find your problem
$13M
A year managed through US GPOs and hospital systems, including Duke Health, Cleveland Clinic, NYU Langone and Mayo Clinic
3 → ~40
Markets opened for a patented medical device portfolio, with revenue up about 75% a year
21 yrs
In medical devices, pharma and healthcare SaaS; commercial leadership since 2011

Problems we solve

Revenue has stalled and nobody can say why
Activity is high, forecasts miss and deals stall at different stages. You need a clear, data-based read on where revenue is leaking.
Commercial Gap Analysis →
A launch, new market or raise is coming
Clearance, funding or a new region is close, and pricing, channel and the first commercial hires aren't decided yet.
Go-to-Market Strategy →
Sales still depend on the founder
Deals close because one person is in the room. There is no repeatable process, qualification or forecast behind them.
Enterprise Sales Playbook →
Hospitals, GPOs and distributors aren't buying
Value-analysis committees, tenders and distributor economics are slowing every deal. You need someone who has sold through them.
Go-to-Market Strategy →
You need a senior commercial leader, but not a full-time hire yet
The stage calls for a CRO or CCO's judgment and ownership of the number, at a fraction of the cost and commitment.
Fractional CRO / CCO →
An investor needs a commercial view, fast
A portfolio company is underperforming, or a deal needs pressure-testing on pricing, P&L assumptions and launch plan.
Diligence & Interim Leadership →

Services

Commercial Gap Analysis
Fixed scope · quoted after a health check
A diagnostic of your go-to-market, pipeline, team and pricing, with a prioritized plan of what to fix first. The fastest way to know where revenue is leaking.
Go-to-Market Strategy
Scoped after a health check
Market and segment priorities, pricing, channel (direct, distributor or both), hospital and GPO access, and a launch plan with the first commercial hires, built before launch rather than after.
Enterprise Sales Playbook
Scoped after a health check
Ideal customer profile, qualification (MEDDIC), messaging, deal stages and forecasting, built for complex, multi-stakeholder healthcare sales.
Fractional Advisor
Scoped after a health check
A senior commercial sounding board for founders and leadership teams, on a light monthly retainer.
Fractional CRO / CCO
Scoped after a health check
Part-time commercial leadership: building the team, running the pipeline and owning the number until a full-time leader is warranted.
Diligence & Interim Leadership
Scoped after a health check
Commercial diligence for investors and boards, and full-time operating leadership for companies in transition, with P&L ownership and a clear hand-off plan.

Results Ossei has delivered

$5M → $20M
AI digital health company: built the commercial and operating foundation from scratch as COO and equity partner
Read the story
Challenge
An early-stage AI digital health company with a promising product and no commercial or operating structure.
The work
As COO and equity partner, built the sales process, commercial infrastructure and operating cadence from zero, and advised the CEO on growth decisions.
Result
Company valuation grew from $5M to $20M.
$750K → $2.7M
Medical glove portfolio turnaround with full P&L ownership
Read the story
Challenge
An underperforming medical glove portfolio that needed an owner.
The work
Took full P&L ownership, rebuilt the account plan and led a cross-functional team of up to 12.
Result
Portfolio grew from $750K to $2.7M.
$20K → $10M
PPE category built through direct manufacturer sourcing, on 3–5 year national supply contracts
Read the story
Challenge
A small PPE line with no dedicated sourcing or major-account strategy.
The work
Built direct manufacturer sourcing and sold into national pharmacy chains, health systems and distributors on 3–5 year supply contracts.
Result
Category grew from roughly $20K to $10M between 2018 and 2021.
3 → ~40
Markets for a patented medical device portfolio as VP Sales & Marketing, with revenue up about 75% a year
Read the story
Challenge
Sales of about $1.2M in three markets, underperforming distributors and regulatory approvals taking close to a year.
The work
Rebuilt the sales process, partner scorecards, pricing and territory model; replaced 6 distributors with 10 stronger partners; built relationships with regulators.
Result
Revenue up about 75% a year, roughly 40 markets, and approval times cut to about six months.
$0 → ~$5M
New regional business built from zero on five-year government tenders
Read the story
Challenge
Markets dominated by incumbent manufacturers and distributors, where entering alone couldn't win tenders.
The work
Partnered with a US manufacturer, reworked sourcing to meet tender pricing, and built a mix of large and local distributors to reach hospitals, clinics and pharmacies.
Result
About $1M a year within nine months on two tenders, growing to roughly $5M.

Accounts sold into include Walgreens, CVS, McKesson, Cardinal Health and AmerisourceBergen, along with hospitals, GPOs and distributors in about 40 countries. Hospital-system contracts have included Duke Health, Cleveland Clinic, NYU Langone and Mayo Clinic.

How an engagement works

1 · Free health check
A 30-minute conversation about where revenue is coming from, where it's stuck, and what's coming next.
2 · Diagnose
A clear read on the gaps, using your pipeline, customer and team data, not opinions.
3 · Build
The playbook, processes and hires that close those gaps, built with your team.
4 · Embed and hand off
Stay alongside until the system runs without us, then hand it to your team.

Who we work with

Pre-launch medical device companies
Cleared or close to it, with no commercial team yet. We build the go-to-market plan, pricing and first hires before launch, not after.
Scaling MedTech, pharma and healthcare SaaS companies
Past early traction, moving from founder-led selling to a repeatable, forecastable revenue engine.
Investor-backed portfolio companies
PE and VC-backed companies after a raise or acquisition, where the plan calls for growth and integration on a deadline.
Investors and boards
Independent commercial diligence and readiness reviews for portfolio companies before the next round or exit.

Great products don't sell themselves, especially in healthcare.

Healthcare buyers move carefully, decide by committee and expect proof. Clearance, funding and a strong product get you to the starting line. What turns them into revenue is a commercial engine built for how your market actually buys.

Why MediMavericks

An operator, not a slide deck
Built commercial functions from zero, carried quota and owned P&Ls. The advice comes from having done the work.
Senior from day one
You work directly with Ossei, not a junior team learning on your account.
Specialists when you need them
When a project needs more than commercial leadership, we bring in trusted partners Ossei has worked alongside: regulatory and quality specialists, commercialization and market-validation advisors, and digital health product and clinical experts. One point of contact, the right depth.
Fluent in how healthcare buys
Pharma, medical devices and healthcare SaaS, across pharmacy chains, health systems, distributors and about 40 international markets.
Built to hand off
The goal is a system your team runs without us: documented, measurable and owned in-house.
Ossei Williams

Led by Ossei Williams

I've spent 21 years in medical devices, pharma and healthcare SaaS, starting in operations in 2005 and leading commercial teams since 2011. I've sold into hospitals, GPOs, national pharmacy chains and distributors across about 40 markets, at Medicom Group (a global medical products manufacturer of about $1B), MEDISCA (about $500M), and as VP Sales & Marketing at Innoventive Solutions and Partner & COO of an AI digital health company.

I lead every MediMavericks engagement myself. When a project needs specialist depth, I bring in partners I've worked with and trust. I also advise Sononurse, a pre-launch surgical patient-safety device, and I'm completing an MBA at the University of Cumbria. More on LinkedIn.

How ready is your commercial engine?

Ten quick questions, about two minutes. You'll get a score, your biggest gap and where to start. Nothing is stored or sent.

Strategy
We have a written ideal customer profile and know which segment we win in.
Strategy
Our pricing and value story have been tested with real buyers.
Strategy
We have a 12-month go-to-market plan tied to revenue targets.
Process
Deals move through defined stages with clear exit criteria.
Process
We qualify every opportunity the same way.
Process
Our forecast usually lands within 10–15% of actuals.
People
Someone other than the founder can close a deal.
People
We know which commercial hire comes next, and why.
Engine
We know our pipeline coverage and stage-by-stage conversion rates.
Engine
We generate new pipeline in a repeatable way, beyond referrals.
0 of 10 answered